The demand for digital health technology is increasing. According to Digital Authority Partners, “Telemedicine, Artificial Intelligence (AI) -enabled medical devices, and blockchain electronic health records are just a few concrete examples of the digital transformation in healthcare, affecting the way we interact with healthcare professionals and how our data is are to be completely redesigned “. shared between providers and how decisions are made about our treatment plans and health outcomes. ”That’s where a company like AI / ML innovations (CSE: AIML) (OTC: AIMLF) and its subsidiary Health Gauge, a leading provider of digital health solutions, may be able to help.
Health Gauge is a leader in digital health solutions – in a potential $ 245 billion global digital health monitoring market – poised to transform the traditional health industry by delivering AI innovations and services that support the Improve health outcomes while reducing costs and burdens on congested health infrastructure. In fact, digital health solutions can save the healthcare industry billions of dollars – and allow caregivers, patients, and healthcare professionals to easily access essential health information much faster. In addition to AI / ML innovations, there are other top companies to check out Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF), Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), Empower Clinics Inc. (CSE: CBDT) (OTC: EPWCF) and CloudMD Software & Services Inc. (TSXV: DOC) (OTC: DOCRF).
Health selected by AI / ML to participate in leading accelerator programs
AI / ML Innovations Inc. (CSE: AIML) (OTCQB: AIMLF) has been selected to participate in several of the leading U.S. accelerator programs designed to advance promising digital health technology companies toward profitability.
“The fact that Health Gauge has been selected from among a select few to participate in these world-class programs is real evidence and further validation of Health Gauge’s transformative technology and business model,” said Tim Daniels, Executive Chairman of AI / ML Innovations Inc “Health Gauge continues to benefit from the knowledge and relationships gained through participating in these programs.”
Health Gauge has successfully participated in and benefited from the following programs:
MATTER.Health (Chicago, IL): Health Gauge was one of only five Canadian companies selected to participate in Chicago’s globally recognized MATTER.health program in 2019. Health Gauge remains an alumni organization and maintains connections there in order to use these relationships to further develop Health Gauge market penetration strategy.
MATTER.health is recognized worldwide for the quality of its program, which creates positive momentum for digital healthcare companies and executives to interact in solving next generation solutions. Based on MATTER’s non-profit and no-equity model, the community is a neutral platform where healthcare entrepreneurs can meet industry leaders, scientists and clinicians from around the world to help develop health and life sciences the next generation to work together.
CELS-SFO Canadian Entrepreneurs in Life Sciences (Silicon Valley, CA): Health Gauge was selected from a group of just ten companies to participate in its program, which aims to promote innovative Canadian life science companies in the San Francisco Bay Area and Silicon Valley through community power and connections and access to capital in Silicon Valley.
CELS is the leading Canadian program helping Canadian innovation-driven companies get started in the United States and providing experienced and influential connections in Silicon Valley and the United States.
Neuchip (Austin, TX): Health Gauge was asked by Newchip in 2020 to participate in their health technology-centric business development program that attracts and works with companies from around the world. Health Gauge uses Newchip’s variety of online services to connect with the community in the United States.
The Newchip Accelerator Program is designed to function like an Executive MBA program. Their network includes a team of seasoned mentors and a global community of founders, angel investors, and venture capitalists.
Other related developments around the markets are:
Revive Therapeutics Ltd., a specialized life science company focused on the research and development of therapeutics for medical needs and rare diseases is pleased to announce that it has an agreement with the University of Health Sciences Antigua to collaborate on the use of the Revive’s novel psychedelic-assisted therapies and pioneering clinical research and development of psychedelics in Antigua and Barbuda.
Mydecine innovation group has selected substance abuse and smoking cessation as the first target indications for its proprietary psychedelic molecule MYCO-004. MYCO-004 is a patch-administered tryptamine compound and its properties include short duration (less than two hours), transdermal, precise dosing, and long-term compound stability. Mydecine said it selected substance abuse disorder and smoking cessation for MYCO-004 as it addresses underserved and drastic treatment needs. The company found that 19.7 million American adults had an addiction disorder. Of these, 8.5 million suffer from both substance abuse disorder and mental health disorder.
Empower Clinics Inc. announced the signing of six letters of intent (LOIs) to open medical health centers with REXALL / PHARMA PLUS PHARMACIES LTD, the second largest pharmacy group in Canada. It is suggested that Empower will sublet these first six locations to build and operate health centers to advance Empower’s national clinic expansion strategy. Services include comprehensive primary care led by doctors, as well as paramedical services with doctors providing services such as chiropractic, physiotherapy and more. The beneficiaries of these services include the pharmacies’ large existing customer base as well as patients in the larger communities that each location will serve.
CloudMD Software & Services Inc., a health technology company that is revolutionizing medical care announced its financial results for the first quarter ended March 31, 2021. All financial information is presented in Canadian dollars unless otherwise stated. Dr. Essam Hamza, CEO of CloudMD, commented, “We are excited to announce our record financial results for the first quarter of 2021, which continue to improve quarter by quarter. The first quarter was a period of transformation for CloudMD as we completed 5 acquisitions, added $ 13 million in annual revenue, and laid the foundation for our Enterprise Health Solutions business. I am very proud of the strategic roadmap we have created and the team’s ability to execute our growth strategy. We identified key acquisition targets that were synergistic with our overall vision, and we continue to focus on building a complete healthcare ecosystem that provides connected, holistic care. We continue to integrate all of our capabilities into one comprehensive platform that forms the basis for scale and expansion. “
Disclaimer / Except for the historical information contained herein, the matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results, performance or accomplishments expressed therein statements are implied. Winning Media is not registered with any financial or securities regulator and does not provide investment advice or recommendations to readers of this press release. In order to make specific investment decisions, readers should seek advice for themselves. AI / ML Innovations Inc. paid three thousand five hundred dollars for advertising and marketing services distributed by Winning Media. Winning Media is only remunerated for its services in the form of cash. Winning Media owns ZERO shares in AI / ML Innovations Inc. Please click here for the full disclaimer.